Relationship between Plasma Hypoxia Inducible Factor 1α in Type 2 Diabetes Mellitus with Malignancy and Without Malignancy

Rusdiana  Rusdiana; Sry Suryani Widjaja; Maya Savira; Dedi Ardinata

doi:10.3889/oamjms.2020.5138

Authors

Rusdiana Rusdiana Department of Biochemistry, Medical Faculty, Universitas Sumatera Utara, Jl. dr. Medan, Indonesia http://orcid.org/0000-0002-7308-9291
Sry Suryani Widjaja Department of Biochemistry, Medical Faculty, Universitas Sumatera Utara, Jl. dr. Medan, Indonesia
Maya Savira Department of Physiology, Medical Faculty, Universitas Sumatera Utara, Jl. dr. Medan, Indonesia
Dedi Ardinata Department of Physiology, Medical Faculty, Universitas Sumatera Utara, Jl. dr. Medan, Indonesia

DOI:

https://doi.org/10.3889/oamjms.2020.5138

Keywords:

DM type 2, Fasting Blood Sugar, Hba1c, HIF-1α

Abstract

BACKGROUND: Diabetes mellitus was associated with hypoxia condition and result ischemia and induced neovascularization and other forms of the cell adaptation in response to the tissue concentrations of low oxygen levels. Hypoxia-Inducible Factor 1 alpha a marker of the cell adaptation as a hypoxic cell response which was due of chronic hiperglycemia.

AIM: The aim of this study to know the relationship between Hba1c and plasma HIF-1 α level at type 2 diabetes mellitus patients.

METHODS: The cross-sectional study design using the 89 samples of diabetes mellitus patients who attended Murni Teguh Hospital in Medan of Indonesia country. The inclusion criteria of the samples were all the patients diagnosed with type 2 diabetes mellitus both the sexes. Body mass index, blood pressure, and disease history six socioeconomic status was recorded. The laboratory parameters, including fasting blood sugar and Hba1c were examined by Murni Teguh Hospital Laboratory.

RESULTS: The result of the study we found that there was no significant difference the hypoxia-inducible factor 1α level (HIF-1α) at type 2 diabetes mellitus with malignancy was higher compared at type 2 diabetes mellitus without malignancy.

CONCLUSION: The patient’s type 2 diabetes mellitus with the high HIF-1α levels have a poor prognosis compared with the lower levels because the high HIF-1α will tend to have a risk complication of malignancy or the other complication of diabetes mellitus.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Alberti KG. Screening and diagnosis of prediabetes: Where are we headed? Diabetes Obes Metab. 2007;9 Suppl 1:12-6. https://doi.org/10.1111/j.1463-1326.2007.00764.x PMid:17877542

Verma M, Paneri S, Badi P, Raman PG. Effect of increasing duration of diabetes mellitus Type 2 on glycated hemoglobin and insulin sensitivity. Indian J Clin Biochem. 2006;21(1):142-6. https://doi.org/10.1007/bf02913083 PMid:23105586

Cameron NE, Eaton SE, Cotter MA, Tesfaye S. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia. 2001;44(11):1973-88. https://doi. org/10.1007/s001250100001 PMid:11719828

Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, et al. Diabetes and cancer: A consensus report. Diabetes Care. 2010;33(7):1674-85. https://doi. org/10.2337/dc10-0666 PMid:20587728

Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: Implications for O2 sensing. Science. 2001;292(5516):464-8. https://doi.org/10.1126/science.1059817 PMid:11292862

Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, et al. Targeting of HIF-alpha to the Von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 2001;292(5516):468-72. https://doi.org/10.1126/science.1059796 PMid:11292861

Catrina SB, Okamoto K, Pereira T, Brismar K, Poellinger L. Hyperglycemia regulates hypoxia-inducible factor-1alpha protein stability and function. Diabetes. 2004;53(12):3226-32. https://doi.org/10.2337/diabetes.53.12.3226 PMid:15561954

Hu M, Polyak K. Microenvironmental regulation of cancer development. Curr Opin Genet Dev. 2008;18(1):27-34. PMid:18282701

Talks KL, Turley H, Gatter KC, Maxwell PH, Pugh CW, Ratcliffe PJ, et al. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol. 2000;157(2):411-21. https://doi.org/10.1016/ s0002-9440(10)64554-3 PMid:10934146

Hoo Y, Mahmoud AA. Hypoxia inducible factor-1α in Type 2 diabetes mellitus with microalbuminuria and retinopathy. Majalah Kedokt Bandung Med J. 2014;46(2):100-5.

Ece H, Cigdem E, Yuksel K, Ahmet D, Hakan E, Oktay TM. Use of oral antidiabetic drugs (Metformin and Pioglitazone) in diabetic patients with breast cancer: How does it effect serum Hif-1 alpha and 8Ohdg levels? Asian Pac J Cancer Prev. 2012;13(10):5143-8. https://doi.org/10.7314/ apjcp.2012.13.10.5143 PMid:23244125

Martin A, Komada MR, Sane DC. Abnormal angiogenesis in diabetes mellitus. Med Res Rev. 2003;23(2):117-45. https://doi. org/10.1002/med.10024 PMid:12500286

Eltzschig HK, Carmeliet P. Hypoxia and inflammation. N Engl J Med. 2011;364(7):656-65. PMid:21323543

Ke QD, Costa M. Hypoxia-inducible factor-1 (HIF-1). Mol Pharmacol. 2006;70(5):1469-80. https://doi.org/10.1124/ mol.106.027029 PMid:16887934

Bento CF, Pereira P. Regulation of hypoxia-inducible factor 1 and the loss of the cellular response to hypoxia in diabetes. Diabetologia. 2011;54(8):1946-56. https://doi.org/10.1007/ s00125-011-2191-8 PMid:21614571

Li G, Lu WH, Ai R, Yang JH, Chen F, Tang ZZ. The relationship between serum hypoxia-inducible factor 1α and coronary artery calcification in asymptomatic Type 2 diabetic patients. Cardiovasc Diabetol. 2014;13:52. https://doi.org/10.1186/1475-2840-13-52 PMid:24564828

Garcia-Maceira P, Mateo J. Silibinin inhibits hypoxia-inducible factor-1alpha and mTOR/p70S6K/4E-BP1 signalling pathway in human cervical and hepatoma cancer cells: Implications for anticancer therapy. Oncogene. 2009;28():313-24. https://doi. org/10.1038/onc.2008.398 PMid:18978810